Insider Monkey - 2025-05-27 18:24
On Tuesday, Citi downgraded Prime Medicine Inc. (NASDAQ:PRME) from a Buy to a Neutral rating while also significantly reducing its price target from $10 to $1.50. Citi said that this adjustment reflects that the company’s shares are trading near cash, which shows the market’s uncertainty on Prime Medicine’s path to potential value inflection. Despite implementing […]